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The World Health Organization (WHO) has designated 24 
March of each year as ‘World TB Day’, to mark the anniversary 
of Robert Koch’s discovery in 1882 of the cause of tuberculosis 
(TB), Mycobacterium tuberculosis. Regrettably, this is not a day 
for celebration. Instead, governments, policy makers, scientists 
and funders must reflect on the paradoxical fact that, although 
effective and cheap therapy has been available for over 60 
years, TB kills nearly 1.8 million people every year, that is,  
5 000 people every day! Together with HIV/AIDS and malaria, 
TB remains one of the most important causes of death from 
infectious diseases worldwide. World TB Day provides an 
opportunity to reflect on the poor state of TB control globally, 
particularly in sub-Saharan African countries (SSA).1
The WHO, donor governments and other funding agencies 
have focused much of their investments over the past decade 
on TB control, with some measurable success. The WHO 
2009 report2 shows epidemiological evidence of a decrease in 
the number of new cases of TB in China and Asia, although 
the global TB disease burden remains unacceptably high. In 
particular, TB continues to spread relentlessly in high HIV 
endemic SSA, where the absolute number of TB cases continues 
to rise and TB remains the predominant cause of death among 
the HIV infected. Furthermore, the emergence of multidrug-
resistant and more ominously extensively drug-resistant (XDR) 
TB in SSA adds to the growing pressures on health systems and 
national TB programmes, while the recession causes financial 
hardships and compromises TB control efforts in developing 
countries. Creative ideas and pragmatic new strategies are 
urgently required if the TB epidemic in SSA is to be brought 
under control.  Committed research and capacity development 
are central to this.
SAMJ Editor Professor Daniel J Ncayiyana stated in the BMJ 
that ‘Africa’s health challenges are not insurmountable and 
... Africa must look for what South Africa’s President Thabo 
Mbeki characterised as “African solutions to African health 
problems”.3 Only when a critical mass of African researchers 
working on African soil has been restored will Africa generate 
new knowledge relevant to its most pressing health problems.’ 
Since the 1950s, as African countries became independent, 
they embarked on developing their own medical schools and 
training programmes. Many African institutions have not been 
able to develop and sustain their research and development 
(R&D) programmes to international standards, which has long 
been a subject of debate and discussion.4 This is an indictment 
of the former colonial powers for inadequately investing in 
African-led research and training programmes, of current 
Western funders and expatriate-led R&D units in SSA,3,4 and of 
African governments for failing to support and prioritise local 
R&D initiatives. SSA institutions have been plagued by lack 
of funding for R&D and of proper infrastructures, financial 
mismanagement, and trained indigenous staff capable of 
independent local research. Furthermore, an ageing African 
scientific leadership has overlooked the important issue of in-
house mentoring for younger scientists.
R&D and training must be high on the agendas of donor 
agencies and African governments.5 The more developed 
African R&D groups should get out of their bunkers and 
partner with less developed sites within Africa, to enhance 
African R&D and networking. Unfortunately, project grant 
funding from funding agencies has failed in sustaining 
substantial African-led R&D, owing to budgetary and time 
limits. In 2003 a timely new initiative, the European and 
Developing Countries Clinical Trials Partnership (EDCTP), 
was founded by the European Parliament and Council.6 It is 
a partnership of 14 European Union member states, Norway, 
Switzerland, and SSA countries, formed to fund acceleration 
of north-south partnerships on new clinical trial interventions 
(new or improved drugs, vaccines, diagnostics and 
microbicides) in SSA to combat HIV/AIDS, malaria and TB.7 
The aim of integrating these activities is to develop the capacity 
to sustainably conduct clinical trials in SSA.  
The initial jerky start of the EDCTP8 was strengthened by 
a new administration that transformed the EDCTP into an 
important funding body for research and capacity development 
in SSA countries, far surpassing that of traditional Western 
country funders of African R&D.7 The EDCTP seeks to be 
synergistic with other funding bodies and hopes to foster true 
and lasting partnerships between European and southern 
African partners. The active involvement and contribution of 
African scientists may lead to joint ownership of the EDCTP 
programme with European counterparts. Strong commitment 
that moves beyond tokenism is required from African scientists 
to realise these aims. Correctly utilised, these initiatives should 
assist the development of regional networks of excellence in 
sub-Saharan Africa with sustainable R&D programmes that 
should be supported by their local governments.  
All funders of African R&D must join hands with the 
EDCTP initiative to have a multiplier effect. Since the EDCTP 
has taken the lead in supporting the important and neglected 
areas of research and training in Africa, it is anticipated that 
all funding agencies similarly involved will align themselves 
synergistically with EDCTP initiatives. The UK Medical 
Research Council (MRC) is already involved with the EDCTP, 
and provision of MRC co-funding for some EDCTP grant 
calls appears encouraging, but MRC funds are insufficient 
to cover the increase in EDCTP activity. All 16 European 
countries involved in supporting the EDCTP must show their 
support and increase their co-funding of this novel initiative. 
The Wellcome Trust has recently joined the call to strengthen 
capacity for health research in Africa9 and plans to support 
African-led, UK-supported initiatives in training of African 
PhDs.10 It would be prudent for the innovative new strategy 
for Wellcome Trust Fellows’ long-term support initiative also 
to be made available for African scientists. The Wellcome Trust 
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should also consider providing flexible, long-term, auditable 
funding of existing African scientist-led consortia which could 
be commissioned to lead jointly defined and well-developed 
protocols on high-priority R&D projects. Their results would 
improve health outcomes of adults and children in Africa. 
Previously there was nothing to inspire and enthuse African 
scientists, and by default Western scientists continued to lead 
R&D as expatriates in Africa. The commitment by the EDCTP 
has now been translated into practice with 141 projects worth 
255 million Euros already funded, mostly in the past 4 years.7 
This involves 126 institutions in 28 sub-Saharan African 
countries and 43 institutions from 17 European countries and 
51 other partners, a massive investment. These investments 
must be followed up by local governments assisting in 
establishing productive high-quality R&D programmes in SSA. 
The stakes for African scientists and their governments have 
never been higher. Their real challenge remains – to translate 
the substantial EDCTP investment into deliverable and visible 
outputs of properly trained staff, improved and sustainable 
research infrastructures, effective R&D networks, high-
quality research publications, and research output relevant 
to health policy. SSA countries should rise to this challenge, 
develop African scientist-led R&D programmes and become 
internationally competitive, enabling them to develop their 
own solutions to their own health problems.3 We hope and 
trust that World TB Day 15 years from now will celebrate the 
turn of the tide against TB5 and other killer infectious diseases 
including malaria and HIV/AIDS, saving millions of lives and 
allowing future generations to realise their full potential.
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